Close Menu

NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has launched a pilot surveillance study with South Korea's ATGen Global to evaluate a new method for the early detection of cancer recurrence in triple-negative breast cancer patients. Cynvenio's ClearID test will be combined with ATGen's NK Vue blood test to detect cancer recurrence in women who have previously been treated for triple-negative breast cancer and show no radiographic signs of metastases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.